| Literature DB >> 18594024 |
Maria E Sarasquete1, Ramon García-Sanz, Luis Marín, Miguel Alcoceba, Maria C Chillón, Ana Balanzategui, Carlos Santamaria, Laura Rosiñol, Javier de la Rubia, Miguel T Hernandez, Inmaculada Garcia-Navarro, Juan J Lahuerta, Marcos González, Jesus F San Miguel.
Abstract
We have explored the potential role of genetics in the development of osteonecrosis of the jaw (ONJ) in multiple myeloma (MM) patients under bisphosphonate therapy. A genome-wide association study was performed using 500 568 single nucleotide polymorphisms (SNPs) in 2 series of homogeneously treated MM patients, one with ONJ (22 MM cases) and another without ONJ (65 matched MM controls). Four SNPs (rs1934951, rs1934980, rs1341162, and rs17110453) mapped within the cytochrome P450-2C gene (CYP2C8) showed a different distribution between cases and controls with statistically significant differences (P = 1.07 x 10(-6), P = 4.231 x 10(-6), P = 6.22 x 10(-6), and P = 2.15 x 10(-6), respectively). SNP rs1934951 was significantly associated with a higher risk of ONJ development even after Bonferroni correction (P corrected value = .02). Genotyping results displayed an overrepresentation of the T allele in cases compared with controls (48% vs 12%). Thus, individuals homozygous for the T allele had an increased likelihood of developing ONJ (odds ratio 12.75, 95% confidence interval 3.7-43.5).Entities:
Mesh:
Substances:
Year: 2008 PMID: 18594024 DOI: 10.1182/blood-2008-04-147884
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113